Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Given Average Recommendation of "Hold" by Brokerages

Key Points

• Amphastar Pharmaceuticals has received an average recommendation of "Hold" from six brokerages, with four ratings as "hold" and two as "buy".
• The average 1-year price target for the stock is $31.60, with the stock currently trading at approximately $23.86.
• Significant investor activity has been noted, with institutional investors now owning 65.09% of the company's stock, highlighting increased confidence among large shareholders.

Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) have been assigned a consensus recommendation of "Hold" from the six ratings firms that are currently covering the company, Marketbeat reports. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $31.60.

A number of equities research analysts recently issued reports on the company. Bank of America raised their price target on Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the stock a "neutral" rating in a research note on Tuesday, August 26th. Needham & Company LLC upgraded Amphastar Pharmaceuticals from a "hold" rating to a "buy" rating and set a $36.00 target price for the company in a research report on Tuesday, August 12th. Weiss Ratings reiterated a "hold (c-)" rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Piper Sandler decreased their target price on Amphastar Pharmaceuticals from $30.00 to $25.00 and set a "neutral" rating for the company in a research report on Friday, August 8th.

Amphastar Pharmaceuticals Price Performance

Amphastar Pharmaceuticals stock opened at $23.86 on Wednesday. The company has a current ratio of 3.29, a quick ratio of 2.21 and a debt-to-equity ratio of 0.80. The firm has a market capitalization of $1.11 billion, a PE ratio of 8.94 and a beta of 0.75. Amphastar Pharmaceuticals has a 12-month low of $20.39 and a 12-month high of $53.96. The firm has a 50-day moving average price of $27.78 and a 200-day moving average price of $25.35.

Hedge Funds Weigh In On Amphastar Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. GAMMA Investing LLC raised its position in shares of Amphastar Pharmaceuticals by 46.6% in the 1st quarter. GAMMA Investing LLC now owns 1,333 shares of the company's stock worth $39,000 after acquiring an additional 424 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its position in shares of Amphastar Pharmaceuticals by 5.2% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 9,440 shares of the company's stock worth $217,000 after acquiring an additional 465 shares in the last quarter. Hohimer Wealth Management LLC raised its holdings in Amphastar Pharmaceuticals by 6.9% in the first quarter. Hohimer Wealth Management LLC now owns 8,005 shares of the company's stock worth $232,000 after purchasing an additional 520 shares in the last quarter. Signaturefd LLC raised its holdings in Amphastar Pharmaceuticals by 147.7% in the first quarter. Signaturefd LLC now owns 872 shares of the company's stock worth $25,000 after purchasing an additional 520 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its holdings in Amphastar Pharmaceuticals by 13.8% in the first quarter. PNC Financial Services Group Inc. now owns 4,783 shares of the company's stock worth $139,000 after purchasing an additional 580 shares in the last quarter. Institutional investors own 65.09% of the company's stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.